Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-148

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 71288-148). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Carton (100mg Carton 01)

Pemetrexed for Injection, USP 100 mg per vial carton label. This lyophilized powder for intravenous injection is supplied as a single-dose vial. The label includes storage instructions, reconstitution details, and safety warnings noting it as a cytotoxic agent. The product is manufactured for Meitheal Pharmaceuticals Inc. and contains pemetrexed disodium equivalent to 100 mg pemetrexed per vial.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Vial Label (100mg Vial 01)

Label for Pemetrexed for Injection, USP 100 mg per vial injection powder. The label indicates intravenous use only, single-dose vial, with instructions to discard unused portions. Manufactured by Meitheal Pharmaceuticals Inc., the label includes storage instructions and a caution that the product is a cytotoxic agent.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 1 Gram Carton (1g Carton 01)

Carton label for Pemetrexed for Injection, USP 1 gram per vial by Meitheal Pharmaceuticals Inc. The label indicates this is a single-dose vial for intravenous use only and includes a caution that it is a cytotoxic agent. The label lists ingredients for reconstitution and storage instructions, with branding and barcode information.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 1 Gram Vial Label (1g Vial 01)

Label for Pemetrexed for Injection, USP, 1 gram per vial, lyophilized powder for solution. The single-dose vial is indicated for intravenous use only. The label identifies Meitheal Pharmaceuticals Inc. as the labeler and includes storage instructions, a caution for use, and a barcode.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 500 mg Carton (500mg Carton 01)

Packaging label for Pemetrexed for Injection, USP 500 mg per vial, a lyophilized powder for intravenous injection. The label includes usage instructions, caution as a cytotoxic agent, and storage conditions. It is labeled for Meitheal Pharmaceuticals Inc. and marked as a single-dose vial with barcode and lot information placeholder.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 500 mg Vial Label (500mg Vial 01)

Label for Pemetrexed for Injection, USP, 500 mg per vial, a lyophilized powder for intravenous use. The label includes warnings such as 'Caution: Cytotoxic Agent' and 'For Intravenous Use Only, Single-Dose Vial.' It specifies storage conditions and manufacturer information, Meitheal Pharmaceuticals Inc., Chicago, Illinois.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 750 mg Carton (750mg Carton 01)

Packaging label for Pemetrexed for Injection, USP 750 mg per vial, a lyophilized powder for intravenous solution by Meitheal Pharmaceuticals Inc. The carton displays dosage strength, NDC 71288-147-50, warnings indicating cytotoxic agent and single-dose vial use, preparation instructions, storage conditions, and manufacturer information including Meitheal Pharmaceuticals and Kindos Pharmaceuticals Co., Ltd. A barcode and a QR code with product lot and expiration placeholders are also visible.*

FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 750 mg Vial Label (750mg Vial 01)

Label for Pemetrexed for Injection, USP 750 mg per vial, a lyophilized powder for intravenous use. The label states single-dose vial use and includes storage instructions at 2 to 25°C. It also notes the container is not made with natural rubber latex. The product is labeled by Meitheal Pharmaceuticals Inc., with cautions including 'Cytotoxic Agent.'*

FDA Label Image

Figure 1 (Fig 1 V2)

A survival curve chart comparing overall survival (%) over time in months for two treatment arms: P+B+C (pemetrexed, pembrolizumab, platinum chemotherapy) and P+C (pemetrexed, platinum chemotherapy, placebo). The chart includes a table showing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Fig 2)

A Kaplan-Meier survival curve graph comparing survival probability over 30 months between two chemotherapy regimens: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). The x-axis shows survival time in months, and the y-axis shows survival probability. Patient counts at risk are listed below the graph for each time point.*

FDA Label Image

Figure 3 (Fig 3)

A survival probability graph comparing two treatment groups: Pemetrexed + Cisplatin (PC) versus Gemcitabine + Cisplatin (GC) over a 30-month period. The x-axis shows survival time in months, and the y-axis displays survival probability. Below the graph is a table listing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Fig 4)

A survival probability graph comparing two treatments over time in months. The solid line represents Pemetrexed plus Cisplatin (PC), and the dotted line represents Gemcitabine plus Cisplatin (GC). The x-axis shows survival time in months up to 30, and the y-axis shows survival probability from 0 to 1. Below the graph, patient risk counts at various time points are listed for both treatment groups.*

FDA Label Image

Figure 5 (Fig 5)

This chart depicts a survival probability curve comparing Pemetrexed injection powder for solution against placebo over a survival time in months. The graph shows survival probabilities on the y-axis and time in months on the x-axis, with patient numbers at risk reported below the x-axis for both Pemetrexed and placebo groups.*

FDA Label Image

Figure 6 (Fig 6)

A Kaplan-Meier survival curve comparing survival probability over time in months between Pemetrexed and placebo groups. The solid line represents Pemetrexed, showing higher survival probability over time, while the dotted line represents placebo with lower survival probability. The chart also includes the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Fig 7)

A survival probability Kaplan-Meier curve comparing patients treated with Pemetrexed versus placebo over a 42-month period. The x-axis shows survival time in months, and the y-axis presents survival probability. Patient counts at risk for both groups are listed below the graph at various time points.*

FDA Label Image

Figure 8 (Fig 8)

A Kaplan-Meier survival curve comparing survival probability over time (months) between Pemetrexed and placebo groups. The chart shows higher survival probability for Pemetrexed over placebo. Below the x-axis is a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 9 (Fig 9 V2)

A Kaplan-Meier survival curve chart comparing survival probability over time in months for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The chart includes a table below showing the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Structural Formula (Pem Struct)

Chemical structure of pemetrexed disodium heptahydrate, shown with sodium ions and water molecules as commonly presented in pharmaceutical labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.